CD276 and pancreatic neoplasm: In the present study, we developed CD276 Dash CAR-T manufactured with less time and presented evidence that Dash CAR-T exhibited higher stemness and enhanced pancreatic tumor control compared to conventional CAR-T in vitro and in vivo.